GlobeImmune Statistics
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
GlobeImmune has 5.75 million shares outstanding.
| Current Share Class | 5.75M |
| Shares Outstanding | 5.75M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.00 |
| PB Ratio | 0.00 |
| P/TBV Ratio | 0.00 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.28
| Current Ratio | 2.28 |
| Quick Ratio | 2.10 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -66.24% and return on invested capital (ROIC) is -41.40%.
| Return on Equity (ROE) | -66.24% |
| Return on Assets (ROA) | -10.25% |
| Return on Invested Capital (ROIC) | -41.40% |
| Return on Capital Employed (ROCE) | -36.77% |
| Weighted Average Cost of Capital (WACC) | -1,806.00% |
| Revenue Per Employee | 2.07M |
| Profits Per Employee | -689,528 |
| Employee Count | 3 |
| Asset Turnover | 0.49 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +9,900.00% in the last 52 weeks. The beta is -329.14, so GlobeImmune's price volatility has been lower than the market average.
| Beta (5Y) | -329.14 |
| 52-Week Price Change | +9,900.00% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.43 |
| Relative Strength Index (RSI) | 42.65 |
| Average Volume (20 Days) | 3,915 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.14 |
Income Statement
In the last 12 months, GlobeImmune had revenue of 6.21 million and -2.07 million in losses. Loss per share was -0.36.
| Revenue | 6.21M |
| Gross Profit | 4.13M |
| Operating Income | -2.07M |
| Pretax Income | -2.07M |
| Net Income | -2.07M |
| EBITDA | -1.94M |
| EBIT | -2.07M |
| Loss Per Share | -0.36 |
Balance Sheet
The company has 8.69 million in cash and n/a in debt, with a net cash position of 8.69 million or 1.51 per share.
| Cash & Cash Equivalents | 8.69M |
| Total Debt | n/a |
| Net Cash | 8.69M |
| Net Cash Per Share | 1.51 |
| Equity (Book Value) | 2.15M |
| Book Value Per Share | 0.37 |
| Working Capital | 5.30M |
Cash Flow
In the last 12 months, operating cash flow was -5.90 million and capital expenditures -11,805, giving a free cash flow of -5.92 million.
| Operating Cash Flow | -5.90M |
| Capital Expenditures | -11,805 |
| Free Cash Flow | -5.92M |
| FCF Per Share | -1.03 |
Margins
Gross margin is 66.52%, with operating and profit margins of -33.30% and -33.30%.
| Gross Margin | 66.52% |
| Operating Margin | -33.30% |
| Pretax Margin | -33.30% |
| Profit Margin | -33.30% |
| EBITDA Margin | -31.25% |
| EBIT Margin | -33.30% |
| FCF Margin | n/a |
Dividends & Yields
GlobeImmune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -32.85% |
| Shareholder Yield | -32.85% |
| Earnings Yield | -359,753.91% |
| FCF Yield | -1,028,991.13% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GlobeImmune has an Altman Z-Score of -30.24 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -30.24 |
| Piotroski F-Score | 2 |